A registrational bioequivalence study of APL 130227 (sublingual apomorphine) for Parkinson's disease.

Trial Profile

A registrational bioequivalence study of APL 130227 (sublingual apomorphine) for Parkinson's disease.

Planning
Phase of Trial: Phase III

Latest Information Update: 21 Oct 2016

At a glance

  • Drugs Apomorphine (Primary) ; Apomorphine (Primary)
  • Indications Parkinson's disease
  • Focus Pharmacokinetics; Registrational
  • Most Recent Events

    • 21 Oct 2016 This trial was planned by Cynapsus Therapeutics . The Company has now been acquired by Sunovion Pharmaceuticals , according to a Sunovion Pharmaceuticals media release.
    • 04 Apr 2016 According to Cynapsus media release, company plans to file NDA with the FDA near the end of 2016 or in early 2017.
    • 26 Apr 2013 Planned End Date changed from 1 Sep 2013 to 1 Mar 2014, as reported in a Cynapsus Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top